Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Современные возможности персонализированной терапии метастатической меланомы кожи
Современные возможности персонализированной терапии метастатической меланомы кожи
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В последние годы отмечается значительный прогресс в лечении метастатической меланомы (ММ). Появление новых таргетных лекарственных препаратов способствует персонализации противоопухолевой терапии с высокой ожидаемой эффективностью. BRAF-ингибиторы достоверно увеличивают безрецидивную и общую выживаемость, частоту объективных ответов у больных ММ. Вемурафениб является первым селективным BRAF-ингибитором, зарегистрированным в России. В данной статье приводится анализ современных данных по клиническому применению препарата у больных диссеминированной меланомой кожи.
Ключевые слова: метастатическая меланома, таргетная терапия, BRAF-ингибиторы, вемурафениб.
Key words: metastatic melanoma, targeted therapy, BRAF-inhibitors, vemurafenib.
Ключевые слова: метастатическая меланома, таргетная терапия, BRAF-ингибиторы, вемурафениб.
________________________________________________
Key words: metastatic melanoma, targeted therapy, BRAF-inhibitors, vemurafenib.
Полный текст
Список литературы
1. Демидов Л.В., Орлова К.В. Индивидуализация лекарственного лечения меланомы кожи. Практ. онкология. 2013; 14 (4): 239–46.
2. Злокачественные новообразования в России в 2010 г. (заболеваемость и смертность). Под ред. В.И.Чиссова, В.В.Старинского, Г.В.Петровой. М.: Изд-во ФГБУ МНИОИ им. П.А.Герцена, 2013.
3. American Cancer Society. Cancer facts and figures 2013.
4. Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22: 1118–25.
5. Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24: 4738–45.
6. Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62: 6997–7000.
7. Chapman PB, Hauschild A, Robert C et al. Updated overall survival (OS) results for BRIM3, a phase III randomized, open label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF V600E mutated melanoma. J Clin Oncol 2012; 30: 15. ASCO Ann Meeting. Abstr. 8502.
8. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745–51.
9. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med 2011; 364: 2507–16.
10. Colombino M, Capone M, Lissia A et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012; 30 (20): 2522–9.
11. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–54.
12. Davis MJ, Schlessinger J. The genesis of Zelboraf: Targeting mutant B-Raf in melanoma. J Cell Biol 2012; 199: 15–9.
13. Fecher L, Cummings S, Keefe M, Alani R. Toward a molecular classification of melanoma. J Clin Oncol 2007; 25 (12): 1606–20.
14. Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008. 2.0. Cancer Incidence and Mortality Worldwide: IARC Cancer Base 2010; 10.
15. Fisher R, Larkin J. Treatment of brain metastases in patients with melanoma. Lancet Oncol 2012; 13: 434–5.
16. Flaherty K, Puzanov I, Sosman J. Phase I study of PLX 4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009; 27: 15. Abstr. 9000.
17. Garbe C, Peris K, Hauschild A et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010; 46: 270–83.
18. Hauschild A et al. Presented at the 10th International Meeting of the Society for Melanoma Research 2013. Philadelphia, Pennsylvania.
19. Hodi F, O’Day S, McDermott D et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363 (8): 711–23.
20. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC vs. combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11: 75–81.
21. Jackson J. PLX4032 targets melanomas with BRAF Mutation: Clinical Trials on Melanoma and Other Cancers Show Great Results 2009.
22. Jakob JA, Bassett RL et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012; 118: 4014–23.
23. Korn EL, Liu PY, Lee SJ et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527–34.
24. Larkin J, Vecchio MD, Ascierto PA et al. Vemurafenib in patients with BRAF V600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 2014; http://dx.doi.org/10.1016/S1470-2045(14)70051-8
25. McArthur GA, Chapman PB, Robert C et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; http://dx.doi.org/10.1016/S1470-2045 (14)70012-9
26. Menzies AM, Haydu LE, Visintin L et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012; 18: 3242–9.
27. Middleton MR, Grob JJ, Aaronson N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158–66.
28. Ribas A et al. Oral presentation EADO 2014.
29. Robert C et al. ASCO 2012. Abstr. LBA 8509.
30. Sasse AD, Sasse EC, Clark LG et al. Chemoimmunotherapy vs. chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007; 1: CD005413.
31. Schuchter L. Presented at the 10th International Meeting of the Society for Melanoma Research 2013. Philadelphia, Pennsylvania.
32. Sinha R, Edmonds K, Newton-Bishop JA et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 2012; 167: 987–94.
33. Smith F, Downey S, Klapper J et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008; 14 (17): 5610–8.
34. Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855–67.
35. World Health Organization. Skin cancers 2013; http://www.who.int/ uv/faq/skincancer/en/index1.html; www.cancer.org/acs/groups/content/@epidemiologysurveilance
2. Злокачественные новообразования в России в 2010 г. (заболеваемость и смертность). Под ред. В.И.Чиссова, В.В.Старинского, Г.В.Петровой. М.: Изд-во ФГБУ МНИОИ им. П.А.Герцена, 2013.
3. American Cancer Society. Cancer facts and figures 2013.
4. Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22: 1118–25.
5. Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24: 4738–45.
6. Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62: 6997–7000.
7. Chapman PB, Hauschild A, Robert C et al. Updated overall survival (OS) results for BRIM3, a phase III randomized, open label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF V600E mutated melanoma. J Clin Oncol 2012; 30: 15. ASCO Ann Meeting. Abstr. 8502.
8. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745–51.
9. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med 2011; 364: 2507–16.
10. Colombino M, Capone M, Lissia A et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012; 30 (20): 2522–9.
11. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–54.
12. Davis MJ, Schlessinger J. The genesis of Zelboraf: Targeting mutant B-Raf in melanoma. J Cell Biol 2012; 199: 15–9.
13. Fecher L, Cummings S, Keefe M, Alani R. Toward a molecular classification of melanoma. J Clin Oncol 2007; 25 (12): 1606–20.
14. Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008. 2.0. Cancer Incidence and Mortality Worldwide: IARC Cancer Base 2010; 10.
15. Fisher R, Larkin J. Treatment of brain metastases in patients with melanoma. Lancet Oncol 2012; 13: 434–5.
16. Flaherty K, Puzanov I, Sosman J. Phase I study of PLX 4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009; 27: 15. Abstr. 9000.
17. Garbe C, Peris K, Hauschild A et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010; 46: 270–83.
18. Hauschild A et al. Presented at the 10th International Meeting of the Society for Melanoma Research 2013. Philadelphia, Pennsylvania.
19. Hodi F, O’Day S, McDermott D et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363 (8): 711–23.
20. Huncharek M, Caubet JF, McGarry R. Single-agent DTIC vs. combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001; 11: 75–81.
21. Jackson J. PLX4032 targets melanomas with BRAF Mutation: Clinical Trials on Melanoma and Other Cancers Show Great Results 2009.
22. Jakob JA, Bassett RL et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012; 118: 4014–23.
23. Korn EL, Liu PY, Lee SJ et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527–34.
24. Larkin J, Vecchio MD, Ascierto PA et al. Vemurafenib in patients with BRAF V600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 2014; http://dx.doi.org/10.1016/S1470-2045(14)70051-8
25. McArthur GA, Chapman PB, Robert C et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; http://dx.doi.org/10.1016/S1470-2045 (14)70012-9
26. Menzies AM, Haydu LE, Visintin L et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012; 18: 3242–9.
27. Middleton MR, Grob JJ, Aaronson N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158–66.
28. Ribas A et al. Oral presentation EADO 2014.
29. Robert C et al. ASCO 2012. Abstr. LBA 8509.
30. Sasse AD, Sasse EC, Clark LG et al. Chemoimmunotherapy vs. chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007; 1: CD005413.
31. Schuchter L. Presented at the 10th International Meeting of the Society for Melanoma Research 2013. Philadelphia, Pennsylvania.
32. Sinha R, Edmonds K, Newton-Bishop JA et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 2012; 167: 987–94.
33. Smith F, Downey S, Klapper J et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008; 14 (17): 5610–8.
34. Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855–67.
35. World Health Organization. Skin cancers 2013; http://www.who.int/ uv/faq/skincancer/en/index1.html; www.cancer.org/acs/groups/content/@epidemiologysurveilance
Авторы
С.А.Проценко1, А.В.Новик1, 2, З.Ю.Ахаева1, А.С.Жабина1, Е.Н.Имянитов1, А.И.Семенова1
1 ФГБУ Научно-исследовательский институт онкологии им. Н.Н.Петрова Минздрава России, Санкт-Петербург;
2 ГБОУ ВПО Санкт-Петербургская государственная педиатрическая медицинская академия Минздрава России
1 ФГБУ Научно-исследовательский институт онкологии им. Н.Н.Петрова Минздрава России, Санкт-Петербург;
2 ГБОУ ВПО Санкт-Петербургская государственная педиатрическая медицинская академия Минздрава России
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.